Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Jordi Gines"'
Autor:
Marta García-Recio, Antonia Cladera, Leyre Bento, Julia Dominguez, Silvia Ruiz de Gracia, Francesca Sartori, Raquel Del Campo, Lucia García, Carmen Ballester, Jordi Gines, Joan Bargay, Antonia Sampol, Antonio Gutiérrez
Publikováno v:
PLoS ONE, Vol 12, Iss 6, p e0179595 (2017)
Central nervous system (CNS) lymphomatosis is a fatal complication of aggressive non-Hodgkin lymphoma (NHL). In lymphoblastic or Burkitt lymphoma, without specific CNS prophylaxis the risk of CNS relapse is 20-30%. DLBCL has a lower risk of relapse (
Externí odkaz:
https://doaj.org/article/bf02b3d19a3a49bdb87593d63047c55e
Autor:
Antonio Gutiérrez, Leyre Bento, Antonia Maria Bautista-Gili, Francesc Garcia, Jordi Martinez-Serra, Blanca Sanchez, Clara Martorell, Jordi Gines, Lucia Garcia, Eva Gimeno, Mariana Ferraro, Raquel Del Campo, Joan Bargay, Albert Perez, Javier Vercher, Miguel Scaff, Ana Pacheco, Carmen Ballester, Florencia Garcia, Rafael Ramos, Antonio Salar, Joan Besalduch
Publikováno v:
PLoS ONE, Vol 10, Iss 4, p e0123978 (2015)
DLBCL is an aggressive lymphoma treated with R-CHOP. Recently, attempts have been made to improve the outcome by increasing both dose-density and intensity but there have been no benefits in terms of survival. When treating malignancies RDI is import
Externí odkaz:
https://doaj.org/article/d7e01404cc3342578811658f0dda65ea
Autor:
Bàrbara Boyeras, Antonio Gutierrez, Fernando do Pazo, Olga Delgado Sánchez, Clara Martorell, Marta García-Recio, Leyre Bento, Jordi Gines, Antonia Sampol
Publikováno v:
ClinicoEconomics and Outcomes Research. 11:695-701
Purpose The availability of different routes of administration of rituximab, with different dosing and times of infusion in the day care unit, raises the question of which formulation would be the best in terms of direct cost, particularly with the a
Autor:
Francesc Mestre, Paloma López, Marta García-Recio, Leyre Bento, Jordi Martinez-Serra, Antonia Sampol, Jordi Gines, Antonio Gutierrez, Jaime Daumal, Rafael Yus Ramos
Publikováno v:
OncoTargets and therapy
Marta Garcia-Recio,1,2 Jordi Martinez-Serra,1 Francesc Mestre,2,3 Leyre Bento,1,2 Jordi Gines,4 Rafael Ramos,2,5 Jaime Daumal,2,6 Paloma López,2,3 Antonia Sampol,1 Antonio Gutierrez1,2 1Hematology Department, 2Lymphoma Unit, 3Radiotherapy Department
Autor:
Carmen Ballester, Raquel Del Campo, Antonia Sampol, Francesca Sartori, Lucia García, Silvia Gràcia, Marta García-Recio, Joan Bargay, Leyre Bento, Julia Dominguez, Jordi Gines, Antonio Gutierrez, Antonia Cladera
Publikováno v:
PLoS ONE, Vol 12, Iss 6, p e0179595 (2017)
PLoS ONE
PLoS ONE
Central nervous system (CNS) lymphomatosis is a fatal complication of aggressive non-Hodgkin lymphoma (NHL). In lymphoblastic or Burkitt lymphoma, without specific CNS prophylaxis the risk of CNS relapse is 20–30%. DLBCL has a lower risk of relapse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a80c75c7b99e17d58b7f92f2c2c5063a
https://doi.org/10.1371/journal.pone.0179595
https://doi.org/10.1371/journal.pone.0179595
Autor:
Sandra Pérez-León, Jordi Gines, Antonia Sampol, Marta Garcia Recio, Sara Aida Jiménez-Julià, Leyre Bento, Jordi Martinez-Serra, Antonio Gutierrez
Publikováno v:
Blood. 132:5337-5337
Introduction: Six percent of all non-Hodgkin lymphomas (NHL) cases are mantle cell lymphoma (MCL). MCL has a poor prognosis and is considered incurable with current strategies. Intensive approaches are not applicable to most these patients considerin
Autor:
Lucia García, Antonia Sampol, Blanca Sanchez-Gonzalez, Marta Garcia Recio, Antonio Gutierrez, Leyre Bento, Antonio Salar, Jordi Gines, Beatriz Robredo, Sandra Pérez-León, Sara Aida Jiménez-Julià, Jordi Martinez-Serra
Publikováno v:
Blood. 132:5339-5339
Introduction : Follicular lymphoma (FL) is an indolent non-Hodgkin lymphoma that represents 15-30% of all newly diagnosed lymphomas. It is characterized by a high rate of response followed by continuous relapses being considered incurable with standa
Autor:
Jordi Gines, Marta García-Recio, Jordi Martinez-Serra, Rafael Yus Ramos, Antonio Gutierrez, Jaime Daumal, Antonia Sampol, Leyre Bento
Publikováno v:
OncoTargets and therapy
Marta Garcia-Recio,1,2 Jordi Martinez-Serra,1,2 Leyre Bento,1,2 Rafael Ramos,2,3 Jordi Gines,4 Jaime Daumal,5 Antonia Sampol,1,2 Antonio Gutierrez1,2 1Service of Hematology, 2Instituto de Investigación Sanitaria de Palma (IdISPa), 3Service of Pathol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df706b8f987ec6c5a64acf77ce7588fc
https://doi.org/10.2147/ott.s107893
https://doi.org/10.2147/ott.s107893
Autor:
Carlos Saus, Antonio Gutierrez, Joan Besalduch, Joana M. Plazas, Rafael Ramos, Elena Maffiotte, Matias Diaz, Jordi Gines, Juan Carlos Amat, María Navarro-Palou, Jordi Martinez-Serra, Oliver Vögler, Regina Alemany, Teresa Ros, Teresa Bex, Javier Martín
Publikováno v:
European Journal of Pharmacology. 658:57-64
Trabectedin, a naturally occurring substance isolated from the Caribbean marine invertebrate Ecteinascidia turbinata, is the active compound of the antitumor drug Yondelis®. The mechanism of action of Trabectedin has been attributed to interactions
Autor:
Joan Besalduch, Antonio Galmés, Jordi Gines, Antonia Sampol, Javier Martin, Jordi M. Serra, Lorenzo Serra-Moisés, Antonio Gutierrez, María A. Navarro, Carlos Saus, Juan Carlos Amat, Oliver Vögler, Regina Alemany, Teresa Ros
Publikováno v:
Molecular Pharmacology. 73:1679-1687
Non-small-cell lung cancer (NSCLC) is characterized by severe resistance to chemotherapy. Here, we demonstrate that A549 adenocarcinoma cells permanently differentiate with the antimetabolites methotrexate (MTX) and gemcitabine (GE) when blocking the